CRISPRi screening identifies SON and MAP4K1 as regulators of type III cytokine expression in innate lymphoid cells
The Journal of Immunology · 2026
DOI: 10.1093/jimmun/vkag110 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2026. Verfasst von Rachel A Brown und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, United States. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Immunity, Innate, Lymphocytes, DNA-Binding Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, Ohio State University Comprehensive Cancer Center.
Abstract (Originalsprache)
The cytokines interleukin (IL)-22 and IL-17 are secreted by innate and adaptive immune cells to drive “type III” responses that protect against extracellular pathogens, promote mucosal barrier integrity, and foster microbiota homeostasis. However, dysregulation of IL-22 and/or IL-17 contributes to autoimmunity, chronic inflammation, and malignancy. Thus, a deeper understanding of mechanisms regulating type III cytokine production could provide new therapeutic targets for a spectrum of immune-mediated diseases. Toward this goal, we performed a genome-wide CRISPR inhibition (CRISPRi) screen to identify factors that regulate IL-22/IL-17 expression in a murine type III innate lymphoid cell (ILC3) model, MNK3, following stimulation with IL-23 and IL-1β. In addition to previously known regulators of type III cytokines, including IL-23 receptor components IL23R and IL12Rβ1, the screen identified a large set of new factors that either potentiate or attenuate expression of IL-22 and/or IL-17. A subset of these novel factors was chosen for validation, from which two were selected for further study. Knockdown of nuclear protein, SON, which binds both DNA and RNA, impaired expression of IL12Rβ1 at the levels of de novo transcription and RNA processing. The second, MAP4K1 (HPK1), is a serine/threonine kinase that is required for IL-22 but not IL-17 expression. Depletion of MAP4K1 in MNK3 also enhanced expression of the type I cytokine, IFN-γ, which was co-expressed with IL-17, a phenotype reminiscent of pathogenic Th17 cells. Together, results from the CRISPRi screen broaden our understanding of the factors involved in type III immune responses and offer new targets for modulating IL-22/17 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, United States.
- Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, OH, United States.
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, United States.
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- Ohio State University Comprehensive Cancer Center
Zitieren
APA
Brown, R. A., Dangel, A. W., Saini, A., Collins, P. L., Colonna, M., & Oltz, E. M. (2026). CRISPRi screening identifies SON and MAP4K1 as regulators of type III cytokine expression in innate lymphoid cells. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkag110
Vancouver
Brown RA, Dangel AW, Saini A, Collins PL, Colonna M, Oltz EM. CRISPRi screening identifies SON and MAP4K1 as regulators of type III cytokine expression in innate lymphoid cells. The Journal of Immunology. 2026. doi:10.1093/jimmun/vkag110
BibTeX
@article{Brown2026,
author = {Brown, Rachel A and Dangel, Andrew W and Saini, Ankita and Collins, Patrick L and Colonna, Marco and Oltz, Eugene M},
title = {CRISPRi screening identifies SON and MAP4K1 as regulators of type III cytokine expression in innate lymphoid cells},
journal = {The Journal of Immunology},
year = {2026},
doi = {10.1093/jimmun/vkag110}
}
EUVIMED